Use of cookies
Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)
2018.06.25
Active substance: filgrastim, pegfilgrastim, lipegfilgrastim, lenograstim
In agreement with the Federal Institute for Drugs and Medical Devices (BFARM), the marketing authorisation holders are circulating information on the risk of aortitis associated with the administration of granulocyte colony-stimulating factors (G-CSF).
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN